araag2/HINT huggingface dataset:
Clinical trial NCT00603239 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes

          -  If treated with a thiazolidinedione (TZD) alone, the TZD dose must have been stable
             for at least 120 days

          -  The dose of TZD must be: Rosiglitazone (≥4 mg/day) or pioglitazone (≥30 mg/day)

          -  The metformin dose has been stable for at least 90 days

          -  Have suboptimal glycemic control as evidenced by an HbA1c between 7.1% and 10.0%,
             inclusive.

          -  Have a body mass index (BMI): 25 kg/m2 < BMI < 45 kg/m2.

        Exclusion Criteria:

          -  Have participated in this study previously or any other study using exenatide
             (AC2993/LY2148568) or glucagon-like peptide-1 (GLP-1) analogs, or have been previously
             treated with exenatide or GLP-1 analogs

          -  Have participated in an interventional medical, surgical, or pharmaceutical study (a
             study in which an experimental, drug, medical, or surgical treatment was given) within
             30 days of screening. This criterion includes drugs that have not received regulatory
             approval for any indication at the time of study entry.

          -  Have been treated with exogenous insulin for more than 1 week within the 2 months
             prior to screening

          -  Used drugs for weight loss (e.g., orlistat, rimonabant, sibutramine, or similar
             over-the-counter medications) within 3 months prior to screening.

          -  Are currently treated with any of the following excluded medications:

               -  Sulfonylurea or meglitinide derivatives (e.g., repaglinide or nateglinide) within
                  3 months prior to screening

               -  Alpha-glucosidase inhibitor (e.g., miglitol or acarbose) within 3 months of
                  screening

               -  Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin or vildagliptin)
                  within 3 months prior to screening

               -  Pramlintide acetate injection within 3 months prior to screening

               -  Drugs that directly affect gastrointestinal motility, including, but not limited
                  to: Metoclopramide, cisapride, and chronic macrolide antibiotics

               -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid
                  therapy (excluding topical and inhaled preparations) or have received such
                  therapy within the 4 weeks immediately preceding study start
Clinical trial NCT01232569 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tocilizumab 162 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, ≥ years of age.

          -  Moderate to severe rheumatoid arthritis of ≥ 6 months duration.

          -  Receiving treatment on an outpatient basis.

          -  Swollen joint count (SJC) ≥ 6 (66 joint count) and tender joint count (TJC)≥ 8 (68
             joint count) at screening and study start.

          -  On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior
             to study start.

        Exclusion Criteria:

          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned
             major surgery within 6 months following randomization.

          -  Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's
             Syndrome with rheumatoid arthritis is allowed.

          -  Functional class IV as defined by the American College of Rheumatology (ACR)
             Classification of Functional Status in Rheumatoid Arthritis.

          -  Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or
             rheumatoid arthritis before the age of 16 years.

          -  Prior history of or current inflammatory joint disease other than rheumatoid
             arthritis.

          -  History of malignancy, active or recurrent infections, positive to hepatitis B surface
             antigen or hepatitis C antibody, active tuberculosis, serious allergy to biologics, or
             a history of diverticular disease or other symptomatic GI conditions that might
             predispose to perforations.

        Other inclusion and exclusion criteria applied to the study.
Clinical trial NCT00485758 (phase 3, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: er niacin/laropiprant, comparator : placebo (unspecified)
SMILES: CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients between the ages of 18 to 80 years with Type 2 Diabetes who are on a stable
             dose of antidiabetic medication for at least 3 months

        Exclusion Criteria:

          -  Patients taking Cholestin, niacin (>50 mg/day), fibrate therapy, hormonal
             contraceptives, intermittent Hormone Replacement Therapy, or certain corticosteroids

          -  Patients with any of the following conditions: active liver disease or kidney disease,
             poorly controlled high blood pressure, active peptic ulcer, or other heart or blood
             diseases

          -  Patients with abnormal laboratory results from a blood test that will be given before
             starting the study
Clinical trial NCT00189826 (phase 3, status: completed)
Conditions: liver transplantation
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: tacrolimus
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients receiving a primary, split liver or a whole liver graft from a cadaveric
             donor with compatible ABO blood type.

        Exclusion Criteria:

          -  Patients receiving a multi-organ transplant or having previously received an organ
             transplant (including liver re-transplantation).

          -  Patients with severe diarrhoea, vomiting, active peptic ulcer or gastrointestinal
             disorder that may affect the absorption of tacrolimus.

          -  Patients with serum creatinine > 200 µmol/l..
Clinical trial NCT00082095 (phase 3, status: terminated)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pegylated liposomal doxorubicin, capecitabine
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    the study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in
    20 months
  
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically or pathologically proven metastatic breast cancer

          -  Eastern Cooperative Oncology Group performance status between 0-2

          -  Adequate bone marrow, renal and liver functions within normal limits

          -  Left ventricular ejection fractions more than 45% measured by multiple gated
             acquisition scan or echocardiogram within 6 weeks of randomization

        Exclusion Criteria:

          -  Prior chemotherapy for metastatic disease (hormonal or chemotherapy in adjuvant
             setting and hormonal therapy in metastatic setting is allowed)

          -  Prior treatment with capecitabine or pegylated liposomal doxorubicin in the adjuvant
             setting (prior anthracyclines up to certain dose limit is allowed)

          -  Evidence of brain metastases unless previously treated and asymptomatic for 3 months
             or greater

          -  History of cardiac disease with New York Heart Association Class II or greater or
             clinical evidence of congestive heart failure

          -  Anthracycline resistant disease (locally recurrent or metastatic disease while on
             adjuvant anthracycline therapy or relapse less than 18 months after therapy
             completion)
Clinical trial NCT01307319 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis, sar
ICD codes: J30.2, B97.21, C22.4, C46.0, C46.1, C46.2, C46.3, C46.4
Drugs: bdp hfa, placebo nasal aerosol
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects 6 to 11 years of age, as of the Screening Visit (SV)

          -  A documented history of SAR to a relevant seasonal allergen (tree/grass pollen) for a
             minimum of two years immediately preceding the study Screening Visit (SV).

          -  A demonstrated sensitivity to at least one seasonal allergen (tree/grass pollen) known
             to induce SAR through a standard skin prick test.

          -  Other criteria apply

        Exclusion Criteria:

          -  History of physical findings of nasal pathology, including nasal polyps or other
             clinically significant respiratory tract malformations, recent nasal biopsy, nasal
             trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa
             (all within the last 60 days prior to the Screening Visit [SV])

          -  History of a respiratory infection or disorder (including, but not limited to
             bronchitis, pneumonia, chronic sinusitis or influenza,) within the 14 days preceding
             the Screening Visit (SV), or development of a respiratory infection during the Run-in
             Period.

          -  Active asthma requiring treatment with inhaled or systemic corticosteroids and/or
             routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene
             antagonists). History of intermittent use (less than or equal to 3 uses per week) of
             inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable

          -  Have any conditions that are judged by the investigator to be clinically significant
             and/or affect the subject's ability to participate in the clinical trial

          -  Other criteria apply
Clinical trial NCT01208402 (phase 3, status: terminated)
Conditions: high-risk, non-cardiovascular surgeries
ICD codes: Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: esmolol
SMILES: COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    baxter has terminated the study for inadequate enrollment rate accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Males or Females

          2. Age > 40y/o

          3. Scheduled high risk (ASA II-IV) non-cardiac surgery with anticipated 12 hour
             post-operative ICU care

          4. Written informed consent

          5. Patients on a stable chronic oral beta-blocker therapy

          6. Revised Cardiac Risk Index 1(below) Cardiac Risk Index 1 or greater (below)

               -  a history of coronary disease

               -  a history of congestive heart failure

               -  a history of treated diabetes

               -  a history of cerebrovascular disease

               -  a history of chronic renal failure

        Exclusion Criteria:

          1. Active bleeding

          2. Untreated left main disease

          3. Active cardiac condition (eg unstable angina pectoris, acute exacerbation of CHF,
             serious arrhythmias, symptomatic valve disease)

          4. Preoperative positive troponin T

          5. Contraindication for esmolol use

          6. Previous allergy or intolerance to esmolol

          7. Cancer with an expected life expectancy < 6 months

          8. Pregnancy or lactating or planning to become pregnant

          9. Failure to provide informed consent, unable to understand or follow instructions.

         10. History of drug allergy or idiosyncrasy to beta-adrenergic drugs

         11. Recent history (within 1 year) of drug or alcohol abuse

         12. Patients with a Pacemaker

         13. Abnormal liver function Child-Pugh - B

         14. Body Mass Index > 45

         15. Reactive airway disease (defined as a history of hospitalization with status
             asthmaticus within the past one year)

         16. Surgery scheduled to begin after 2pm
Clinical trial NCT00171652 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: diclofenac sodium gel 1%
SMILES: OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Eligibility criteria:

        Key Inclusion criteria:

        • Osteoarthritis of the hand

        Key Exclusion Criteria:

          -  Other rheumatic disease, such as rheumatoid arthritis

          -  Active gastrointestinal ulcer during the last year

          -  Known allergy to analgesic drugs
Clinical trial NCT01833533 (phase 3, status: completed)
Conditions: chronic hepatitis c infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-450/r/abt-267, abt-333, ribavirin, placebo for ribavirin
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females must be practicing specific forms of birth control on study treatment, or be
             post-menopausal for more than 2 years or surgically sterile

          -  Chronic hepatitis C, genotype 1a-infection (HCV RNA level greater than or equal to
             10,000 IU/mL at screening)

          -  Subject has never received antiviral treatment for hepatitis C infection

          -  No evidence of liver cirrhosis

        Exclusion Criteria:

          -  Significant liver disease with any cause other than HCV as the primary cause

          -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody

          -  Positive screen for drugs or alcohol

          -  Significant sensitivity to any drug

          -  Use of contraindicated medications within 2 weeks of dosing

          -  Abnormal laboratory tests
Clinical trial NCT00468728 (phase 3, status: completed)
Conditions: clostridium infections, diarrhea
ICD codes: A05.2, A04.71, A04.72, B96.7, K59.1, R19.7, P78.3, K58.0, K58.9
Drugs: par-101/opt-80, vancomycin
SMILES: CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\C(=O)OC(C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males/females with CDAD

          -  Females must use adequate contraception

          -  Signed informed consent

        Exclusion Criteria:

          -  Life-threatening CDAD

          -  Toxic megacolon

          -  Pregnant

          -  Concurrent use of diarrheal agents

          -  Participation in other trials
Clinical trial NCT01399723 (phase 3, status: completed)
Conditions: pneumonia
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: amoxicillin, benzyl penicillin
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical signs of WHO-defined severe pneumonia

          -  Age 2 months to 59 months

        Exclusion Criteria:

          -  Clinical signs of WHO-defined very severe pneumonia

          -  Clinical or laboratory diagnosis of meningitis

          -  Clinical diagnosis of severe malnutrition (marasmus/kwashiorkor)

          -  Clinical or laboratory diagnosis of severe anaemia requiring transfusion

          -  HIV-exposure on rapid HIV antibody test (only observational data will be collected
             from these patients)

          -  Elimination of signs of severe pneumonia in a child with wheeze after outpatient
             bronchodilator therapy

          -  Chronic condition that may underlie or contribute to a presentation with respiratory
             distress such as: known chronic renal or cardiac disease, presence of cerebral palsy
             predisposing child to aspiration/hypostatic pneumonia

          -  Established bronchiectasis or congenital abnormality of the lower respiratory tract

          -  Upper airway obstruction producing stridor

          -  Admission from outpatient clinic specifically for treatment of TB

          -  Referral from another inpatient facility following treatment with injectable
             antibiotics for more than 24 hours or because the initial regimen is considered to
             have failed

          -  Documented history of >48hours treatment with oral amoxicillin

          -  Failure to obtain informed consent

          -  Penicillin allergy
Clinical trial NCT01556646 (phase 3, status: completed)
Conditions: cirrhosis, hepatic encephalopathy, hyponatremia
ICD codes: K74.3, K74.4, K74.5, K74.60, K74.69, P78.81, K70.30, E51.2, G93.40, G93.41, G93.49, I67.4, G92.8, G92.9, P74.22, E87.1
Drugs: tolvaptan
SMILES: CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Cirrhosis diagnosed by liver biopsy or radiological evidence of nodular cirrhotic
             liver or varices on endoscopy or laboratory features (platelet count <150,000 with an
             AST/ALT ratio >1).

          -  History of HE controlled on lactulose and/or rifaximin

          -  Last HE episode >2 months prior to enrollment and <2 episodes within 6 months

          -  Mini-mental status exam score ≥25

          -  Serum sodium <130mg/dl within the last 14 days and the day of enrollment

          -  Availability of a caregiver

          -  Able to undergo MR of the head

        Exclusion Criteria:

          -  Uncontrolled HE manifested by MMSE <25

          -  Alcohol abuse within 3 months

          -  Illicit drug use within 3 months

          -  Psychoactive drug use other than regularly scheduled anti-depressants or methadone.

          -  Contraindication to MR examination (see attached MRI Safety Form)

          -  Placement of a transjugular intra-hepatic portosystemic shunt (TIPS)

          -  Creatinine Clearance less than 10 ml/min or undergoing hemodialysis

          -  HIV infection

          -  Use of azole medications

          -  Pregnancy

          -  Current use of tolvaptan, hypertonic saline or other medical therapies for
             hyponatremia
Clinical trial NCT00267332 (phase 3, status: terminated)
Conditions: cancer, pain
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: modafinil
SMILES: NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Epworth Sleepiness Scale > 10

          -  Etiology of sleepiness is attributed only to opioids

          -  Patient must have been taking an opioid for more than 2 weeks or have been on a
             non-escalating dose of opioids for at least 1 week

          -  Patient must be able to give written informed consent

          -  Age >18 years

        Exclusion Criteria:

          -  Hypersensitivity to modafinil

          -  Mini-Mental Status Exam (MMSE) < 25/30

          -  Renal impairment (calculated creatinine clearance < 40)

          -  Hepatic dysfunction (total bilirubin > 1.8, AST > 75IU/l, ALT > 100IU/l, prothrombin
             time > 40%

          -  Known history of cardiovascular disease (i.e., left ventricular hypertrophy, ischemic
             ECG changes, chest pain, arrhythmia, mitral valve prolapse, recent myocardial
             infarction, unstable angina, uncontrolled hypertension)

          -  Woman who are pregnant, breast-feeding or on hormonal contraception

          -  Patients taking tricyclic antidepressants, CNS stimulants, hormonal contraceptives or
             drugs that are inhibitors or inducers of CYP 3A4
Clinical trial NCT00400153 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: atrovent respimat (20 mcg), combivent mdi (36/206 mcg), combivent respimat (20 mcg/100 mcg), placebo via corresponding inhaler for blinding purposes
SMILES: [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C, [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C, [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Outpatients of either sex, 40 years or older, with a diagnosis of COPD (FEV1 65% predicted
        normal and FEV1/FVC 70%).

        Exclusion Criteria:

        Patients with significant diseases other than COPD that may either put the patient at risk
        because of participation in the study or a disease which may influence the results of the
        study or the patient's ability to participate in the study, with a history of asthma or
        allergic rhinitis, who regularly use daytime oxygen therapy for more than 1 hour per day
        and in the investigator's opinion will be unable to abstain from the use of oxygen therapy
        or using oral corticosteroid me dication at unstable doses (i.e., less than 6 weeks on a
        stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20
        mg every other day will be excluded.
Clinical trial NCT00417222 (phase 3, status: completed)
Conditions: chronic heart failure
ICD codes: I50.812, I50.22, I50.32, I50.813, I50.23, I50.33, I50.42
Drugs: olmesartan medoxomil
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Eligibility criteria:

        Inclusion Criteria:

        Patients who meet all of the following criteria.

          -  Patients with NYHA class II through IV chronic heart failure.

          -  Patients who have a history of hypertension or those who have antihypertensive
             medications.

          -  Patients who are aged 20 years or older and less than 80 years at the entry.

          -  Stable patients who have angiotensin converting enzyme inhibitor and/or beta-blocker.

          -  Patients who do not have angiotensin II receptor blocker.

        Exclusion Criteria:

          -  Patients who have renal dysfunction (serum creatinine >=3.0mg/dL) or those who are
             receiving chronic hemodialysis.

          -  History of drug hypersensitivity to olmesartan.

          -  Patients who have severe liver dysfunction.

          -  History of angioedema.

          -  History of malignant tumor or life-threatening illness of poor prognosis.

          -  Pregnant or possibly pregnant patients.

          -  Cardiovascular surgery within 6months prior to the date of the entry.

          -  Acute myocardial infarction within 6 months prior to the date of the entry.

          -  Percutaneous coronary intervention or stent implantation within 6 months prior to the
             date of the entry.

          -  Other patients deemed unsuitable as subjects of the study by the treating physician.